BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Cellerix, S.L. Receives 900,000 Euro For Advancing Clinical Trials Using Adipose-Derived Stem Cells


2/16/2006 6:44:54 PM

Madrid. February 2006 – Cellerix, a biotechnology company, and the Spanish Innovation Organisation (Empresa Nacional de Innovación, ENISA) signed a participative loan worth 900,000 euros, to be dedicated to Cellerix’s ongoing clinical trials. These funds, awarded by the public company ENISA, a division of the Department of Industry, Tourism and Trade, help Cellerix consolidate its clinical leadership in the use of adipose-derived stem cells. Cellerix is conducting a Phase II trial treating anal fistulas. It is the only company in the world at this stage of development using adult stem cells from adipose tissue as treatment. This product has received orphan status designation by the EMEA for treating this indication in July ’05.

Cellerix, part of the Genetrix Group located in Madrid (Spain), is also developing a skin regeneration product for treating Epidermolysis Bullosa, a rare and currently untreatable illness. By using adult stem cells for therapy, Cellerix offers a real hope to patients suffering from these illnesses to dramatically improve their quality of life, for which there are no satisfactory treatment alternatives.

These types of loans awarded by ENISA allow the Department of Industry, Tourism and Trade to offer invaluable, providing support to companies like Cellerix, by offering these loans at highly discounted interest rates.

About Cellerix Cellerix is a biotechnology company belonging to the Genetrix Group, which actively develops and produces innovative medicines based on the use of stem cells of adult origin. The company is engaged in clinical Phase II trials for the treatment of complex perianal fistulas. Operational since 2001, Cellerix is a clinically-focused cell therapy company. The company has a developing product pipeline, targeting niche indications such as anal fistulas and skin regeneration for Epidermolysis Bullosa.



Read at BioSpace.com

Cellerix
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES